摘要：Changes in expression patterns of serum carcinoembryonic antigen at initial diagnosis (CEA In ) and disease progression (CEA Pd ) in lung cancer patients under EGFR-tyrosine kinase inhibitors (TKI) treatment may reflect different tumor progression profiles. Of the 1736 lung cancer patients identified from the cancer registry group between 2011 to 2016, we selected 517 patients with advanced stage adenocarcinoma, data on EGFR mutation status and CEA In , among whom were 288 patients with data on CEA Pd , eligible for inclusion in the correlation analysis of clinical characteristics and survival. Multivariable analysis revealed that CEA In expression was associated with poor progression-free survival in patients harboring mutant EGFR. Moreover, CEA In and CEA Pd were associated with the good and poor post-progression survival, respectively, in the EGFR-mutant group. Cell line experiments revealed that CEA expression and cancer dissemination can be affected by EGFR-TKI selection. EGFR-mutant patients, exhibiting high CEA In (≥5 ng/mL) and low CEA Pd (<5 ng/mL), showed a potential toward displaying new metastasis. Taken together, these findings support the conclusion that EGFR mutation status is a critical factor in determining prognostic potential of CEA In and CEA Pd in patients under EGFR-TKI treatment, and CEA In and CEA Pd are associated with distinct cancer progression profiles.
